Introduction
Maintenance of tissue homeostasis depends on a fine balance between proliferation and apoptosis. Within the complex network of intracellular signal processes, protein kinases and phosphatases play a major role. Kinases of the protein kinase C (PKC) family have been shown to be involved in the signal transduction of a wide range of biological responses, triggering changes in cell morphology, proliferation and differentiation (Ron and Kazanietz, 1999) . The PKCs comprise a family of intracellular serine/threonine-specific kinases, which are depending on the isoform, typically activated by Ca 2 þ , lipid second messengers and/or protein activators. Recently, a group of kinases with PKC-like functional structures has been described. This kinase family consists of PKCm (Johannes et al., 1994) , its mouse homologue termed PKD (Valverde et al., 1994) , PKCn (Hayashi et al., 1999) and PKD2 (Sturany et al., 2001) . All these kinases share structural homology to PKCs with respect to the catalytic domain and to the presence of amino-terminal cysteine fingers defining the structural basis for lipid binding. PKCm/PKD differs from PKC isozymes by an acidic domain (Gschwendt et al., 1997) , a pleckstrin homology domain within the regulatory region (Gibson et al., 1994) and the lack of a typical pseudosubstrate site.
Although PKCm/PKD has been repeatedly reported to be responsible for the triggering of Golgi-mediated transport processes and to be important for the maintenance of Golgi stacks architecture, other cellular functions have been proposed (Van Lint et al., 2002) . PKCm has been shown to participate in the control of keratinocyte proliferation (Rennecke et al., 1999) to counteract TNF-induced apoptosis in HeLa cells (Johannes et al., 1998) , and is probably involved in the function of invadopodia formed by breast cancer cells during invasion of the surrounding tissues (Bowden et al., 1999) . Particularly in the context of breast cancer, PKCm and its upstream activating kinase PKCe seemed to be involved in triggering cellular adhesion processes (Platet et al., 1998; Palmantier et al., 2001; Brandlin et al., 2002) .
The work from different laboratories showed a participation of PKCm/PKD in growth factor-induced signalling processes by differentially triggering the MAP kinase cascades (Van Lint et al., 1998; Bagowski et al., 1999; Hausser et al., 2001 ) accounting for proliferating effects of this enzyme.
Recently, we reported that pancreatic adenocarcinoma cells were resistant to CD95-mediated apoptosis despite constitutive CD95 expression on the cell surface (Ungefroren et al., 1998) . We showed that PKC is involved in establishing this resistant phenotype, partially by activation of NF-kB (Trauzold et al., 2001) . In the present study, we investigated the expression of all known PKC isoforms in three pancreatic carcinoma cell lines in relation to their susceptibility to CD95-mediated apoptosis. Since only PKCm expression correlated with the apoptosis sensitivity, we further elaborated the role of PKCm in the regulation of apoptosis and proliferation of pancreatic adenocarcinoma cells.
Results

PKCm expression correlates with apoptosis resistance of pancreatic cell lines
Since a few years it is known that apoptosis induced by CD95 can be blocked by activation of PKC (Scaffidi et al., 1999; Gomez-Angelats and Cidlowski, 2001 ). In the majority of reports showing antiapoptotic functions of PKC, PMA was used as potent and well-established PKC activator. PKC represents a family of at least 10 functionally and structurally related proteins, and several of them are activated by PMA, but it remains unknown which of the PMA-activated PKC isoforms are involved in this process. We reported that the activation of PKC and NF-kB was involved in establishing a resistant phenotype of pancreatic tumour cells, since inhibition of PKC or NF-kB rendered these cells sensitive (Trauzold et al., 2001) . To explore the potential role of different PKC isotypes in pancreatic cell lines, we first determined the expression level of several PKC isoforms in Colo357, PancTuI and Panc89 cells, and correlated it with their sensitivity to anti-CD95-induced apoptosis. Figure 1 shows the expression of several PKC isoforms determined by Western blot analysis. With the exception of PKCi, which was equally expressed in all cells, the other PKC isoforms showed differential expression patterns. The expression of PKCm was strong in PancTuI and Panc89 cells and much weaker in Colo357 cells. In parallel, sensitivity of cell lines to CD95-mediated apoptosis was estimated. Since, as depicted in Table 1 , PancTuI and Panc89 cells were resistant whereas Colo357 cells were clearly more sensitive to anti-CD95 treatment, the expression pattern of only one of the PKCs, the PKCm, obviously correlated with the sensitivity status of these cells.
Selective inhibition of PKCm sensitizes cells to CD95-mediated apoptosis
Among the differences between PKCm and other members of the PKC family is a markedly reduced sensitivity to common PKC inhibitors (Gschwendt et al., 1996) . Bisindolylmaleimide I is a potent inhibitor of several PKC isoforms but not of PKCm. Goe6983, a strong PKC inhibitor, can be used to demonstrate the participation of either classical and novel PKCs or PKCm in cellular signalling pathways as PKCm is inhibited at micromolar concentrations (IC 50 20 mm), whereas other PKCs are blocked already at nanomolar concentrations (IC 50 7-60 nm). To verify our hypothesis that constitutive PKCm expression protects pancreatic tumour cells from CD95-mediated apoptosis, cells were incubated with Goe6983 at different concentrations prior to addition of the anti-CD95 antibody CH11. As shown in Figure 
PKCm overexpression attenuates sensitivity to CD95-mediated apoptosis
To obtain further insight into the antiapoptotic role of PKCm, we stably transfected CD95-sensitive Colo357 cells expressing only small amounts of PKCm with an expression vector coding for PKCm. As shown by immunoblot analysis of the clone pools (Figure 3a) , a clearly stronger PKCm expression was achieved compared to the parental cell line or clone pools of the vector transfected Colo357. Overexpression of PKCm resulted in a markedly enhanced viability of Colo357 cells treated for 24 h with CH11 antibody (Figure 3b) . Moreover, pretreatment of PKCm-overexpressing cells with PKCm-inhibitor Goe6983 (20 mm) levelled off the differences in the CH11-responsiveness between Colo357/PKCm cells and vector-transfected Colo357 cells. As depicted in Figure 3b , incubation of cells with Goe6983 prior to exposure to CH11 resulted in a low (25-29%) survival rate in both PKCm-expressing as well as control cells.
PKCm overexpression upregulates c-FLIP L and survivin
To elucidate the mechanism of PKCm-mediated apoptosis protection, we investigated some of the potential checkpoints of the apoptosis machinery. A comparison of the CD95 cell surface expression by FACS analysis in Colo357-wild-type, -PKCm-transfected, or -mock-transfected cells revealed no differences among the clone pools (data not shown). Thus, PKCm does not seem to affect apoptosis resistance by modulation of CD95 expression in Colo357 cells. Similarly, neither downregulation of proapoptotic caspase-8, caspase-3, caspase-9 and FADD or enhancement of the expression of antiapoptotic molecules like XIAP, cIAP1 and cIAP2 could be detected by Western blot analysis of PKCm clones (data not shown). Likewise, no differences in the constitutive NF-kB activity nor in the activation of NFkB after CD95 activation were detected by EMSA between Colo357/PKCm and Colo357/vector cells (data not shown).
However, Colo357/PKCm cells expressed elevated levels of c-FLIP L and survivin when compared with control cells (Figure 4a ). Both proteins, while acting in different ways, have repeatedly been shown to protect 
Overexpression of PKCm enhances proliferation and the activity of telomerase
Previously, a growth-promoting role of survivin was demonstrated (Li et al., 1998a) . By microscopical observations, a higher growth rate of PKCm-overexpressing cells was visible. This prompted us to determine the generation time, which was calculated to be approximately 25 h for Colo357 cells, and remained unchanged upon stable vector transfection (see Table 2 ). In contrast, PKCm-overexpressing Colo357 cell pools showed a significant shortening of the doubling time resulting in a generation time of 20 h.
Telomerase activity has been proven to be a reliable marker for proliferation and the differentiation status of cancer cells (Belair et al., 1997) . Recently, the involvement of PKC in the activation of telomerase in breast, cervical and nasopharyngeal cancer cells has been shown (Li et al., 1998b; Kim et al., 2001; Yu et al., 2001) . Consequently, we investigated a possible role of PKCm in the modulation of telomerase. As shown in Figure 5 (upper panel), PKCm-overexpressing Colo357 cells revealed a twofold enhanced telomerase activity compared to cells transfected with the empty vector. Since the higher telomerase activity could either reflect an increased hTERT (human telomerase reverse transcriptase) gene expression or the post-translational modification of telomerase, we quantified the hTERT mRNA by realtime PCR. Figure 5 (lower panel) demonstrates that PKCm overexpression resulted in an upregulation of hTERT expression.
PKCm is overexpressed in ductal pancreatic adenocarcinoma
Both, resistance to apoptosis as well as enhanced proliferation promote tumour growth and metastasis. Our findings showed the importance of PKCm in the control of these processes. To verify the importance of the PKCm in situ, we performed immunohistochemical analyses of 48 human pancreatic adenocarcinoma and 10 normal pancreatic tissue sections evaluating the PKCm protein expression pattern. The intensity of PKCm staining in pancreatic ductal adenocarcinoma sections was assessed in a semiquantitative manner resulting in a score between 0 and 3. Two tumours showed mild staining intensity (score o0.5), 15 tumours were stained moderately (0.5-1.5) and 31 Figure 6 ). The overall staining intensity was high (1.8470.76; rank 2.6). Staining was mainly cytoplasmic (Figure 7c , and d) and less frequently focally membranebound (Figure 7e ). Fibroblasts and inflammatory cells were partly also stained. Preabsorption with blocking peptide eliminated the signal completely ( Figure 7C , inset). Normal pancreatic tissues exhibited marked staining in a subset of acinic cells (Figure 7a, and b) .
Since the ductal cells, the normal counterpart of the ductal carcinomas, showed a heterogeneous PKCm expression, we analysed the small ducts (intercalated and intralobular ducts) and the large ducts (interlobular and larger ducts) separately ( Figure 6 ). In all, 46 of 128 (36%) of the small ducts and 11 of 23 (47.8 %) large ducts expressed PKCm revealing mainly mild or moderate staining intensity. The endocrine pancreatic islets were negative. This staining pattern correlated well with a possible role of PKCm in the secretory pathway of exocrine pancreatic cells, but corroborated a marked overexpression in malignant ductal cells.
Discussion
Despite a huge amount of data concerning the structure and function of PKCs, little is known about the expression and role of particular PKC isoforms in physiology and pathophysiology of pancreatic cells. Recently, we demonstrated that inhibition of PKC sensitized resistant PancTuI cells to death receptormediated apoptosis (Trauzold et al., 2001) . In the present study, we compared the expression of several PKC isoforms in CD95-sensitive Colo357 and two CD95-resistant (PancTuI, Panc89) pancreatic adenocarcinoma cell lines, and found that the expression of only one enzyme, the PKCm, correlated with resistance to CD95-mediated apoptosis. Moreover, inhibitor studies strongly supported a putative role for PKCm in establishing the resistant phenotype. When overexpressed in CD95-sensitive Colo357 cells, PKCm not only protected these cells from apoptosis but in addition strongly increased their proliferation rate and possibly their lifespan by telomerase activation. Both, exaggerated proliferation and the escape from death signalling are features enabling tumour cells to survive the immunological control as well as the radio-and chemotherapy and, in the worst case, to invade other tissues. Importantly, we showed for the first time that PKCm is strongly overexpressed in the ductal epithelial compartment of pancreatic tumour tissues suggesting a crucial role of PKCm for pancreatic tumorigenesis. It has been proposed that interactions of the regulatory subdomains of PKCm with lipids or proteins could regulate the intracellular distribution of PKCm (Van Lint et al., 2002) . In this context, it has been shown that PKCm may be located in the Golgi compartment, in the nucleus and at the plasma membrane probably depending on the type and degree of activation. These in vitro observations are now supported by our evaluation of immunohistochemistry data of PKCm in pancreatic tumour tissue. In most of the cases, a cytoplasmic localization was found. Less frequently a membrane staining was given.
PKCm is a novel serine/threonine-specific protein kinase currently under intense investigation. However, only few reports demonstrated a role of PKCm in growth control, for example, of keratinocytes (Rennecke et al., 1999) or fibroblasts (Zhukova et al., 2001) . Recently, it has been shown that PKCm takes part in the neurotensin-mediated signalling pathway, which induces DNA synthesis in the pancreatic adenocarcinoma cell line Panc1 (Guha et al., 2002) . This is the only report on a specific function of PKCm in pancreatic tumour cells so far. Here, we present strong evidence for the growthenhancing and apoptosis-inhibiting role of PKCm in pancreatic tumour cells. With regard to apoptosis resistance, PKCm/PKD was shown to mediate H 2 O 2 -induced NF-kB activation (Storz and Toker, 2003) . 
PKCl in pancreatic cancer
A Trauzold et al Furthermore, PKCm-transfected HeLa cells revealed reduced sensitivity to TNFa-mediated apoptosis, presumably due to the induction of NF-kB target genes cIAP2 and TRAF1 (Johannes et al., 1998) . Although EMSA analyses revealed no increased CD95-induced NF-kB activity in Colo357/PKCm cells compared to mock-transfected cells, we do not absolutely exclude the involvement of NF-kB in PKCm-mediated survival of these cells. In fact, it has been reported that following TNFa-stimulation PKCm-mediated NF-kB-activation was detectable by luciferase reporter assays but not by EMSA analyses (Johannes et al., 1998) . The authors postulated the PKCm action by a direct modulation of NF-kB transactivating capacity. Since we previously observed a PKC-mediated NF-kB activation following CD95 triggering in PancTuI cells (Trauzold et al., 2001) , we propose that this may be due to different expression patterns of PKC isoforms in PancTuI and Colo357 cells. Interestingly, it has also been reported that treatment of U937 cells with TNFa resulted in the caspase-3-dependent cleavage of PKCm and the generation of a potentially proapoptotic catalytic PKCm domain (Haussermann et al., 1999; Endo et al., 2000) .
Although the detailed mechanisms of PKCm-mediated apoptosis-resistance are still unknown, it is likely that the observed upregulation of c-FLIP L and survivin in conjunction with a decreased Bid cleavage are at least partially responsible for this effect. The c-FLIP L molecule is one of the death-inducing signaling complex (DISC) interacting proteins, which has been shown to inhibit the recruitment of caspase-8 to the CD95/FADD complex and consequently the formation of a functional DISC (Irmler et al., 1997; Krammer, 1999) . Thus, the upregulation of c-FLIP L can indeed protect PKCm-overexpressing cells from CD95-mediated apoptosis. Survivin, which belongs to the family of 'inhibitors of apoptosis' (IAP), suppresses apoptosis by binding and inhibiting caspases (Salvesen and Duckett, 2002) . The observed strong inhibition of PARP cleavage in PKCm-overexpressing cells reveals diminished caspase-3 activity. The decrease in Bid cleavage most likely reflects a reduced activation of caspase-8. However, it cannot be ruled out that PKCm mediates Bid phosphorylation, since it has been shown previously that activation of PKC by PMA inhibits Bid cleavage and protects type II cells from CD95-mediated apoptosis (Scaffidi et al., 1999) . Furthermore, phosphorylation of Bid blocks its cleavage by caspase-8 (Desagher et al., 2001) .
In addition to its caspase inhibiting function, survivin was described as a G2/M associated protein involved in the control of proliferation. Importantly, it has been reported that both proteins, c-FLIP and survivin, are overexpressed in pancreatic tumour tissues (Elnemr et al., 2001; Satoh et al., 2001) .
Telomerase activity has been shown to be upregulated in a majority of human cancer cells contributing to their unlimited proliferation (Holt et al., 1996; Belair et al., 1997) . Highly elevated telomerase activity was detected in 95% pancreatic carcinomas but not in benign pancreatic tumours (Hiyama et al., 1997 ). An involvement of PKCa in telomerase activation in breast cancer cells via phosphorylation of hTERT has recently been reported (Li et al., 1998b) . Furthermore, PKCz has been shown to mediate the telomerase activity in nasopharyngeal cancer cells (Yu et al., 2001) . Here, we present evidence for the first time that expression of PKCm leads to increased hTERT mRNA levels and telomerase activity. Obviously, different isoforms of PKC seem to be involved in the regulation of telomerase in different tumour types and, therefore, more detailed investigations are necessary to unravel the role of certain isoforms with respect to telomerase activity and apoptosis.
Based on our findings on PKCm significantly contributing to the malignant phenotype of pancreatic tumour cells, an antagonistic therapeutic approach is desired. Neuropeptides have been shown to induce a PKC-mediated activation of PKCm (Guha et al., 2002) . Thus, there may be a certain chance to reduce PKCm activity in malignant cells by appropriate antagonists (Heasley, 2001 ). This may also be applicable for pancreatic carcinoma cells being responsive to neuropeptides (Ryder et al., 2001) .
On the other hand, the high levels of PKCm in conjunction with the very high frequency of mutated ras in pancreatic tumours may also offer a therapeutic option. In mutant Ras-expressing thyroid epithelial cells, treatment with PMA resulted in the apoptotic cell death due to acute stimulation of PKC (Hall-Jackson et al., 1998). The authors found PKCa and PKCe, both affected by PMA, to be involved in this process. Since PKCm can also readily be stimulated by PMA (Van Lint et al., 1998) , novel selective drugs can potentially be therapeutically exploited.
In conclusion, we showed that PKCm is strongly expressed in apoptosis-resistant pancreatic adenocarcinoma cells. When artificially elevated in apoptosissensitive, low PKCm-expressing Colo357 cells, PKCm protected these cells from apoptosis possibly by upregulation of c-FLIP L and survivin. Furthermore, Colo357/PKCm cells grew faster than the control cells and showed an enhanced telomerase activity suggesting a positive role of PKCm in the control of cell proliferation. These data, together with the finding that PKCm is overexpressed in pancreatic adenocarcinoma tissues document an important role of PKCm in the pathophysiology of pancreatic adenocarcinoma.
Materials and methods
Culture of cell lines and collection of tissues
Human pancreatic adenocarcinoma cell lines Colo357, PancTuI and Panc89 have been described previously (Ungefroren et al., 1998) . All cells were cultured in RPMI 1640 supplemented with 10% FCS, 2 mm glutamine and 1 mm sodium pyruvate (standard medium). Transfections of Colo357 cells with pcDNA3/PKCm-or pcDNA3-vectors were carried out using the Lipofectamine Plus reagent according to the manufacturer's instructions (Invitrogen, Karlsruhe, Germany). For culturing of stably transfected Colo357 cells, 600 ng/ml of G418 was added to the culture medium.
Induction of apoptosis was performed with an agonistic monoclonal anti-CD95-antibodies clone CH11 (100 ng/ml; Coulter Immunotech, Hamburg, Germany) added to the culture medium for 24 h. For inhibition of PKC, the inhibitors Goe6983 (20-20 000 nm), bisindolylmaleimide I (10-200 nm), or calphostin C (10-500 nm) were added to the medium 30 min prior to the incubation of cells with CH11.
For immunohistochemical analysis, archived formalin-fixed paraffin-embedded tissue blocks of 48 pancreatic ductal adenocarcinoma specimens were analysed. All tumours have been surgically removed by pancreaticoduodenectomy for therapeutic purpose. The differentiation and stage of the tumours have been classified according to the WHO classification system (Hamilton et al., 1996) . Normal pancreatic tissues have been removed from 10 individuals who died of suicide and were obtained from the Department of Forensic Medicine of Semmelweis University (Budapest, Hungary). The pancreata were removed within 1 h after the death according to permission of the local Ethical Commission for Scientific Research (permission number: 140-1/1996) and fixed immediately in 4% buffered formalin. Histological examination of the pancreas tissues revealed no signs of pancreatic disease. Forensic autopsies did not show any organic diseases affecting the pancreas.
Determination of cell doubling time
Colo357/PKCm cells, Colo357/vector cells and Colo357 wildtype cells were seeded in six-well culture plates at a density of 1.5 Â 10 5. per well and grown in triplicates in standard medium. After 20 h, cells were washed once with PBS, harvested by incubation with trypsin/EDTA (0.5% trypsin in PBS) and counted in a CASY1 cell counter (Scha¨rfe System, Reutlingen, Germany). From the remaining wells, medium was replaced every 24 h. Cells were counted at time point 0 (20 h after plating) and 8, 24, 32, 48 h later.
JAM-DNA-fragmentation assay
The JAM assay was performed as previously described (Ungefroren et al., 1998) . The percentage of the target cell viability measured as percentage of high molecular weight DNA retained on glass fibre filters was calculated as: % viability ¼ (E/S ) Â 100, where E (experimental) is cpm of retained DNA in the presence of apoptosis-inducing agent under study and S (spontaneous) is cpm of retained DNA of untreated control cells.
Telomerase activity assay
Telomerase activity was measured by a modified semiquantitative telomere repeat amplification assay (TRAP) as described previously (Klapper et al., 1998) . Briefly, cells recovered from the cell culture were washed in PBS and approximately 5 Â 10 6 cells were resuspended in 50 ml CHAPS lysis buffer (0.5% CHAPS, 10 mm Tris-HCl (pH 7.5), 1 mm MgCl 2 , 1 mm EGTA, 5 mm b-mercaptoethanol, 1 mm AEBSF, 1 U/ml RNAsin (Promega), 10% glycerol). After incubation for 30 min. on ice, cell debris were removed by centrifugation at 20 000 g for 30 min at 41C. The protein concentration of the supernatant was determined with BCA Protein Assay Reagent, Pierce Chemical Co., Rockford, USA, For the TRAP assay, the extracts were diluted appropriately and 100 ng of protein (in 2 ml) was mixed with 48 ml reaction mix containing 20 mm TrisHCl (pH 8.0), 1 mm EGTA, 0.0005% Tween 20, 1.5 mm MgCl 2 , 63 mm KCl, 50 mm each dNTP, 2 U Taq polymerase, 0.001 amol ITAS (internal amplification standard), 10 pmol TS-Primer (5 0 -TAMRA labelled), 10 pmol CX-ext Primer.
After 30 min incubation at 301C, the PCR conditions were as follows: 951C for 3 min and 35 cycles of 951C for 30 s, 501C for 30 s and 721C for 30 s. The PCR products were analysed on an ABI prism 310 capillary electrophoresis unit as described (Krupp et al., 1997) . The area under the first five telomerase peaks were added and divided by the area under the ITAS peak (internal amplification standard). For semiquantitative measurement, dilution series of HL60 extract were analysed in parallel. Linear regression analysis of the telomerase peak/ ITAS ratios of the dilution series was performed (GraphPad Prism for Windows). The values of the experimental samples were calculated according to the regression line and expressed as corresponding nanogram of HL60 protein.
Quantification of hTERT expression
Total RNA was isolated from exponentially growing cells using RNA-pure (PQ-Lab, Erlangen, Germany). The quantification of the hTERT expression was performed by real-time one-step RT-PCR using the LightCycler TeloTAGGG hTERT Quantification Kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. To verify equal RNA concentration and quality of the samples, real-time PCR reactions for the housekeeping gene PBGD (porphobilinogen deaminase) were performed in parallel.
Immunohistochemistry and Western blot detection
Formalin-fixed sections of the human pancreatic ductal adenocarcinomas or normal pancreatic tissue samples were blocked with 3% H 2 O 2 in methanol solution followed by blocking with 4% normal goat serum in PBS. For the PKCm stain, sections were incubated with 4.9 U/ml of PROTEASE (Sigma) in PBS for 15 min at 371C. A rabbit polyclonal antiPKCm antibody (D-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was applied (1 : 200), followed by avidinbiotin-peroxidase detection with the Vectastain-ABC Elite Kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's instructions. For negative control, 20 slides were stained following coincubation of the primary antibody (15 min, 371C) with a 350-fold molar excess of the blocking peptide (D-20, Santa Cruz Biotechnology). The staining intensity of the normal ducts was scored as mild (1), moderate (2) and strong (3). As a result of the heterogeneous PKCm expression in tumours, the stains were evaluated by a semiquantitative method as follows: the staining intensity of the tumour cells was scored from 0 to 3, and the proportion of the positive cells was expressed in percent. The final score (0 to 3) was calculated as product of the staining quality and quantity, for example, 60% of 3 þ 20% of 2 þ 20% of 1 ¼ 2.4. For comparability with the ducts, the scores of the tumour tissues were ranked as mild (score o0.5), moderate (0.5-1.5) and strong (>1.5).
Western blot
To detect the cleavage products of PARP, cells were lysed in 62.5 mm. Tris/HCl, pH 6.8; 6 m urea; 5% 
